These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38043493)

  • 21. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
    Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
    Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling.
    Paraiso IL; Tran TQ; Magana AA; Kundu P; Choi J; Maier CS; Bobe G; Raber J; Kioussi C; Stevens JF
    Front Pharmacol; 2021; 12():643857. PubMed ID: 33959012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice.
    Wu WB; Chen YY; Zhu B; Peng XM; Zhang SW; Zhou ML
    Biochimie; 2015 Aug; 115():86-92. PubMed ID: 26025474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
    Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
    Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
    [No Abstract]   [Full Text] [Related]  

  • 26. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
    Li H; Xi Y; Liu H; Xin X
    Front Nutr; 2022; 9():914079. PubMed ID: 36091227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
    Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
    J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver.
    Qiu Q; Wang W; Zhao X; Chen Y; Zhao S; Zhu J; Xu X; Geng R
    Bioorg Chem; 2020 Nov; 104():104262. PubMed ID: 32919135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
    Radun R; Trauner M
    Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and Structural Optimization of Dual FXR/PPARδ Activators.
    Schierle S; Neumann S; Heitel P; Willems S; Kaiser A; Pollinger J; Merk D
    J Med Chem; 2020 Aug; 63(15):8369-8379. PubMed ID: 32687365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FXR agonists in NASH treatment.
    Adorini L; Trauner M
    J Hepatol; 2023 Nov; 79(5):1317-1331. PubMed ID: 37562746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
    Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
    Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
    Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
    Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis.
    Armstrong LE; Guo GL
    Curr Pharmacol Rep; 2017 Apr; 3(2):92-100. PubMed ID: 28983452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
    Hye Khan MA; Schmidt J; Stavniichuk A; Imig JD; Merk D
    Biochem Pharmacol; 2019 Aug; 166():212-221. PubMed ID: 31129048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists.
    Wang W; Cao Z; Yang Z; Chen Y; Yao H; Zhou D; Ou P; Huang W; Jiao S; Chen S; Chen L; Liu Y; Mao J; Xie J; Xiang R; Yang Y; Chen Y; Yang Y; Tan L; Tang H; Zhang L; Li Z
    Eur J Med Chem; 2023 Oct; 258():115614. PubMed ID: 37413879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SU5, a new Auraptene analog with improved metabolic stability, ameliorates nonalcoholic fatty liver disease in methionine- and choline-deficient diet-fed db/db mice.
    Wen F; Bian D; Wu X; Liu R; Wang C; Gan J
    Chem Biol Drug Des; 2022 Mar; 99(3):504-511. PubMed ID: 35040254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.